Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo

被引:26
作者
Guse, K.
Dias, J. D.
Bauerschmitz, G. J.
Hakkarainen, T.
Aavik, E.
Ranki, T.
Pisto, T.
Sarkioja, M.
Desmond, R. A.
Kanerva, A.
Hemminki, A.
机构
[1] Univ Helsinki, Canc Gene Therapy Grp, Biomedicum, Mol Canc Biol Program, FIN-00290 Helsinki, Finland
[2] Univ Helsinki, Haartman Inst, Biomedicum, FIN-00290 Helsinki, Finland
[3] Univ Helsinki, Cent Hosp, Dept Oncol & Husb, Helsinki, Finland
[4] Univ Dusseldorf, Med Ctr, Dept Obstet & Gynecol, D-4000 Dusseldorf, Germany
[5] Univ Helsinki, Cent Hosp, Transplantat Lab, Helsinki, Finland
[6] Univ Alabama, Ctr Comprehens Canc, Biostat & Bioinformat Unit, Birmingham, AL 35294 USA
[7] Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, Helsinki, Finland
基金
芬兰科学院;
关键词
non-invasive imaging; adenovirus; luciferase; cancer; replication; CRAd;
D O I
10.1038/sj.gt.3302949
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Oncolytic viruses kill cancer cells by tumor-selective replication. Clinical data have established the safety of the approach but also the need of improvements in potency. Efficacy of oncolysis is linked to effective infection of target cells and subsequent productive replication. Other variables include intratumoral barriers, access to target cells, uptake by non-target organs and immune response. Each of these aspects relates to the location and degree of virus replication. Unfortunately, detection of in vivo replication has been difficult, labor intensive and costly and therefore not much studied. We hypothesized that by coinfection of a luciferase expressing E1-deleted virus with an oncolytic virus, both viruses would replicate when present in the same cell. Photon emission due to conversion of D-Luciferin is sensitive and penetrates tissues well. Importantly, killing of animals is not required and each animal can be imaged repeatedly. Two different murine xenograft models were used and intratumoral coinjections of luciferase encoding virus were performed with eight different oncolytic adenoviruses. In both models, we found significant correlation between photon emission and infectious virus production. This suggests that the system can be used for non-invasive quantitation of the amplitude, persistence and dynamics of oncolytic virus replication in vivo, which could be helpful for the development of more effective and safe agents.
引用
收藏
页码:902 / 911
页数:10
相关论文
共 31 条
[1]   Complementary adenoviral vectors for oncolysis [J].
Alemany, R ;
Lai, SP ;
Lou, YC ;
Jan, HY ;
Fang, XM ;
Zhang, WW .
CANCER GENE THERAPY, 1999, 6 (01) :21-25
[2]   Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells [J].
Bauerschmitz, Gerd J. ;
Guse, Kilian ;
Kanerva, Anna ;
Menzel, Artur ;
Herrmann, Isabell ;
Desmond, Renee A. ;
Yamamoto, Masato ;
Nettelbeck, Dirk M. ;
Hakkarainen, Tanja ;
Dall, Peter ;
Curiel, David T. ;
Hemminki, Akseli .
MOLECULAR THERAPY, 2006, 14 (02) :164-174
[3]  
Bauerschmitz GJ, 2002, CANCER RES, V62, P1266
[4]  
BUICK RN, 1985, CANCER RES, V45, P3668
[5]   Adenovirus replication-competent vectors (KD1, KD3) complement the cytotoxicity and transgene expression from replication-defective vectors (Ad-GFP, Ad-Luc) [J].
Habib, NA ;
Mitry, R ;
Seth, P ;
Kuppuswamy, M ;
Doronin, K ;
Toth, K ;
Krajcsi, P ;
Tollefson, AE ;
Wold, WSM .
CANCER GENE THERAPY, 2002, 9 (08) :651-654
[6]  
Hakkarainen T, 2006, INT J MOL MED, V18, P751
[7]  
Hemminki A, 2001, CANCER RES, V61, P6377
[8]  
Hemminki A, 2003, CANCER GENE THER, V10, P583, DOI 10.1038/sj.cgt.7700606
[9]  
Hemminki A, 2002, J NATL CANCER I, V94, P741
[10]   AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma:: A randomised, controlled study [J].
Immonen, A ;
Vapalahti, M ;
Tyynelä, K ;
Hurskainen, H ;
Sandmair, A ;
Vanninen, R ;
Langford, G ;
Murray, N ;
Ylä-Herttuala, S .
MOLECULAR THERAPY, 2004, 10 (05) :967-972